Biomanufacturers Demand Higher Quality Standards in 2016

June 15, 2016
Eric Langer
Eric Langer

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

BioPharm International, BioPharm International-06-15-2016, Volume 2016 ebook, Issue 1
Pages: 18–21

Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.

Quality considerations have always been vital to biotherapeutic developers and CMOs. Yet, in 2016, it seems that these considerations are taking on a new emphasis. One of the main industry trends seen this year-increased attention to continuous bioprocessing-is at least partly driven by the potential for improved product quality.


Download the